WINTON GROUP Ltd Purchases New Position in NeoGenomics, Inc. $NEO

Key Points

• WINTON GROUP Ltd acquired 63,379 NeoGenomics shares during the second quarter, valued at approximately $925,000. Institutional investors collectively own 98.5% of the company.
• Analysts remain generally optimistic, with an overall “Moderate Buy” rating and an average price target of $17.67; several firms recently raised targets to between $16 and $19.
• NeoGenomics exceeded quarterly expectations, reporting adjusted earnings of $0.05 per share versus the $0.03 consensus and revenue of $201.66 million, up 11.2% year over year.

WINTON GROUP Ltd purchased a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 63,379 shares of the medical research company's stock, valued at approximately $925,000.

A number of other large investors have also added to or reduced their stakes in NEO. American Capital Management Inc. purchased a new position in shares of NeoGenomics in the second quarter valued at $32,648,000. Bank of New York Mellon Corp bought a new position in NeoGenomics during the second quarter valued at $10,744,000. Renaissance Technologies LLC bought a new position in NeoGenomics during the first quarter valued at $1,886,000. Sei Investments Co. grew its stake in shares of NeoGenomics by 320.7% in the 1st quarter. Sei Investments Co. now owns 466,199 shares of the medical research company's stock worth $3,459,000 after buying an additional 355,379 shares in the last quarter. Finally, MFG Wealth Management Inc. bought a new stake in shares of NeoGenomics in the 2nd quarter worth about $1,218,000. Institutional investors own 98.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on NEO shares. Needham & Company LLC increased their price target on shares of NeoGenomics from $15.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. TD Cowen reiterated a "buy" rating on shares of NeoGenomics in a report on Wednesday, July 15th. Zacks Research upgraded NeoGenomics from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. Craig Hallum restated a "buy" rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, July 29th. Finally, Benchmark lifted their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $17.67.

NeoGenomics Stock Performance

Shares of NeoGenomics stock opened at $17.32 on Monday. The stock's fifty day moving average is $15.91 and its two-hundred day moving average is $11.76. The company has a market capitalization of $2.23 billion, a PE ratio of -43.30 and a beta of 1.75. The company has a quick ratio of 3.35, a current ratio of 3.60 and a debt-to-equity ratio of 0.48. NeoGenomics, Inc. has a 52 week low of $7.07 and a 52 week high of $19.76.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.02. The business had revenue of $201.66 million during the quarter, compared to the consensus estimate of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The business's revenue for the quarter was up 11.2% compared to the same quarter last year. During the same period last year, the company earned $0.03 earnings per share. As a group, analysts expect that NeoGenomics, Inc. will post -0.09 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer.

Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics.

Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs.

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.